Search COVID-19 Rapid Resource Center or explore resources sorted by Category or Content Type.


IDSA Resources: Pharmacology

SCCM’s COVID-19 Rapid Resource Center now links to pertinent content from the Infectious Diseases Society of America (IDSA) COVID-19 Real-Time Learning Network. These resources are categorized as Pharmacology

The information provided is for educational purposes for SCCM members and the general public. Clicking on these links allows users to leave www.sccm.org. The Society does not control the linked sites or the content on those sites. SCCM does not assume any liability for the content or information contained on these linked sites. Further, SCCM does not assume any liability or warrant with respect to the quality, noninfringement, accuracy, completeness, timeliness, or reliability of such linked sites.You should be aware that other internet sites that link to the Site may contain privacy provisions that differ from these policies. To ensure that your privacy is protected, we recommend that you review the privacy policies of other internet sites you visit.

Tixagevimab & Cilgavimab (Evusheld™) Point-of-Care Reference Tool
Date Added: 5/19/2022
Access a quick point-of-care reference about tixagevimab & cilgavimab.
 
Management of Drug Interactions With Nirmatrelvir/Ritonavir (Paxlovid®): Resource for Clinicians
Date Added: 5/19/2022
This resource is intended to provide information on the management of drug interactions with nirmatrelvir/ritonavir.

CDC/IDSA COVID-19 Clinician Call The Latest on COVID-19 Treatment; Plus Variants Update
Date Added: 3/31/2022
Topics include Update on the Omicron Variant and Its Subline ages, Outpatient Treatment Supply & Distribution Update, COVID-19 Treatment Updates from IDSA’s COVID-19 Rapid Guidelines Panel, Monoclonal Antibody Therapies: What’s In, What’s Out, Outpatient COVID-19 Convalescent Plasma Treatment in Immunocompromised Patients, Emerging Data on Baricite in Hospitalized Patients, Q&A and Discussion – All Presenters
 
The Latest on COVID-19 Treatments (March 12, 2022)
Date Added: 3/31/2022
IDSA COVID-19 Guidelines co-authors Rajesh Gandhi, MD, FIDSA and Adarsh Bhimraj, MD, FIDSA provide the latest information on COVID-19 treatments, including their thoughts on the potential role of combination therapies, newer therapies such as nirmatrelvir and sotrovimab, and President Biden's "Test to Treat" initiative.

Guideline on the Treatment and Management of COVID-19
Date Added: 2/23/2022
Recommendation 1: Among patients hospitalized with COVID-19, the IDSA guideline panel recommends against COVID-19 convalescent plasma. Recommendation 2 (UPDATED): Among ambulatory patients with mild to moderate COVID-19 at high risk for progression to severe disease who have no other treatment options*, the IDSA guideline panel suggests FDA-qualified high-titer COVID-19 convalescent plasma within 8 days of symptom onset rather than no high-titer COVID-19 convalescent plasma.

Nirmatrelvir/Ritonavir (Paxlovid™)
Date Added: 2/16/2022
Nirmatrelvir/ritonavir (brand name Paxlovid™) has been FDA authorized for emergency use to treat mild-to-moderate COVID-19 since December 2021. This reference includes clinical information such as eligibility, dosing and a clinical decision-making aid.

COVID-19 Real-Time Learning Network: Antiviral Updates — Molnupiravir, Paxlovid & Remdesivir
Date Added: 1/12/2022
Antivirals are a class of drug that inhibit viral replication and are commonly used against influenza. According to NIH, antivirals’ role in COVID-19 treatment is to “inhibit viral entry via the angiotensin-converting enzyme 2 (ACE2) receptor and transmembrane serine protease 2 (TMPRSS2); viral membrane fusion and endocytosis; or the activity of the SARS-CoV-2 3-chymotrypsin-like protease (3CLpro) and the RNA-dependent RNA polymerase. Because viral replication may be particularly active early in the course of COVID-19, antiviral therapy may have the greatest impact before the illness progresses to the hyperinflammatory state that can characterize the later stages of disease, including critical illness.”
 
IDSA Guidelines on the Treatment and Management of Patients with COVID-19 
Date Added: 1/4/2022
Coronavirus disease 2019 (COVID-19) is a pandemic with a rapidly increasing incidence of infections and deaths. Many pharmacologic therapies are being used or considered for treatment. Given the rapidity of emerging literature, the Infectious Diseases Society of America (IDSA) identified the need to develop living, frequently updated evidence-based guidelines to support patients, clinicians and other health-care professionals in their decisions about treatment and management of patients with COVID-19. 
 
COVID-19 Therapeutics - Lessons Learned (Podcast)
Date Added: 1/4/2022
COVID-19 Treatment Guideline co-authors Rajesh Gandhi, MD, FIDSA of Harvard University and Adarsh Bhimraj, MD, FIDSA of the Cleveland Clinic give an update on COVID-19 therapeutics and discuss two recently published papers in Clinical Infectious Diseases.
 
CDC/IDSA COVID-19 Clinician Call: Omicron Update Plus the Latest on Molnupiravir
Date Added: 1/4/2022
These webinars, held Saturdays at 3 p.m. ET, focus on timely issues of relevance to clinicians and feature case presentations by experts in the field, synthesis of new data, and an opportunity to engage with colleagues. Topics include The Latest on Molnupiravir, Omicron Update, Viral Surveillance Update, and Addressing Diagnostic Challenges.
 
COVID-19 Therapeutics - Lessons Learned – Podcast
Date Added: 12/16/2021
COVID-19 Treatment Guideline co-authors Rajesh Gandhi, MD, FIDSA of Harvard University and Adarsh Bhimraj, MD, FIDSA of the Cleveland Clinic give an update on COVID-19 therapeutics and discuss two recently published papers in Clinical Infectious Diseases.
 
Vaccine Boosters Versus The Delta Variant (podcast)
Date Added: 11/15/2021
How is the Delta variant impacting COVID-19 vaccine performance? Why are only certain populations being considered for boosters? Steven Pergam, MD, FIDSA of the Fred Hutchinson Cancer Research Center and Walter Orenstein, MD, FIDSA of Emory University answer these questions and more.
 
IDSA Guidelines on the Treatment and Management of Patients with COVID-19
Date Added: 11/15/2021
IDSA resource detailing the therapeutic options for treating COVID-19.
 
Get the Facts: Ivermectin and COVID-19  (Inforgraphic)
Date Added: 11/15/2021
IDSA infographic resource detailing the use of Ivermectin for treating COVID-19.
 
Immunomodulators
Date Added: 9/27/2021
This resource details the use of immunomodulators to treat COVID-19.
 
Additional Dose Administration in Certain Immunocompromised Populations
Date Added: 9/27/2021
This IDSA RTNL update details COVID-19 vaccine administration for immunocompromised patients.
 
Vaccine Education Roundtable: Reaching Vaccine Hesitant Populations, Part 2
Date Added: 9/27/2021
Associate Editor Mati Hlatshwayo Davis, MD, MPH, discussed strategies for reaching vaccine hesitant patients with Raul Macias Gil, MD, Jasmine Marcelin, MD, FACP, FIDSA, and Beth Prusaczyk, PhD, MSW. In the final half of the roundtable, panelists share strategies for discussing vaccine concerns and the crucial role that engaging trusted messengers in local communities has in providing reliable information to build vaccine confidence.   

Vaccine Education Roundtable: Reaching Vaccine Hesitant Populations, Part 1
Date Added: 9/27/2021
Associate Editor Mati Hlatshwayo Davis, MD, MPH, discussed strategies for reaching vaccine hesitant patients with Raul Macias Gil, MD, Jasmine Marcelin, MD, FACP, FIDSA, and Beth Prusaczyk, PhD, MSW. In the first half of the roundtable, panelists discuss the challenges of addressing misinformation, reasons for historical mistrust among various populations and their experiences discussing vaccine concerns with patients.
 
IDSA COVID-19 Real-Time Learning Network: Corticosteroids
Date Added: 5/12/2021
This is a link to the IDSA Real-Time Learning Network external resources regarding the use of corticosteriods for treating COVID-19 infection.
 
IDSA COVID-19 Real-Time Learning Network: COVID-19: Vaccine-induced Immune Thrombotic Thrombocytopenia (Podcast)
Date Added: 5/12/2021
This is a link to the IDSA Real-Time Learning Network external resources regarding the  April 13, 2021, FDA and CDC recommendation to pause the use of the Johnson & Johnson/Janssen COVID-19 vaccine after cases of a rare form of blood clotting were reported. In this episode, produced in partnership with the American Society of Hematology, we explore the topic of vaccine-induced immune thrombotic thrombocytopenia with hematologists.
 
Johnson & Johnson/JanssenCOVID-19 Vaccine
Date Added: 3/4/2021
This is a link to the IDSA Real-Time Learning link covering the newly approved COVID-19 vaccine from Johnson & Johnson/Janssen.  
 
IDSA Guidelines on the Treatment and Management of Patients with COVID-19
Date Added: 2/17/2021
This is a link to the IDSA Real-Time Learning Network external resources regarding guidelines for treating and managing COVID-19 patients. 
 
Vaccine FAQs
Date Added: 2/3/2021
This is a link to the IDSA Real-Time Learning Network external resources regarding COVID-19. This is a link to a page covering COVID-19 FAQs. 
 
Tocilizumab 
Date Added: 2/3/2021
This is a link to the IDSA Real-Time Learning Network external resources regarding tocilizumab and COVID-19. 

Convalescent Plasma
Date Added: 2/3/2021
This is a link to the IDSA Real-Time Learning Network external resources regarding convalescent plasma therapy and COVID-19. 

Vaccines & Immunity 
Date Added: 1/12/2021
As vaccine candidates for COVID-19 continue development, refer here for updates on research and trials. This collection includes preliminary information on distribution planning which will be updated as trials progress.
 
ASCO/IDSA Webinar: The COVID-19 Vaccine & Patients with Cancer 
Date Added: 1/6/2021
This is a link to the IDSA Real-Time Learning Network external resource regarding the COVID-19 Vaccine and patients with cancer.
 
Moderna COVID-19 Vaccine
Date Added: 1/6/2021
This is a link to the IDSA Real-Time Learning Network external resource regarding the Moderna COVID-19 vaccine.

COVID-19 Podcast: The Latest on Monoclonal Antibodies (Dec. 19, 2020)
Date Added: 1/6/2021
While monoclonal antibody treatments have performed well in the fight against COVID-19, administering the drugs can be time-consuming and costly.
 
Monoclonal Antibodies
Date Added: 12/14/2020
Information regarding monoclonal antibodies, a therapeutic agent under investigation for the treatment of COVID-19.

Therapeutics Under Current Investigation
Date Added: 12/14/2020
There are many therapeutics under early investigation for treatment of COVID-19 for which there is currently insufficient clinical data to recommend either for or against. This overview is not a comprehensive summary, but a list of therapeutics with strong biological plausibility that are available in the United States and are or will be studied by clinical trial.
 
Vaccine Development
Date Added: 12/14/2020
The vaccine landscape for COVID-19 is rapidly evolving. This page an overview of publicly available information regarding current vaccine trials.


Estimated Time:

Categories: Disaster, Infection, Pharmacology,
Content Type: External Resource,